Program
pembrolizumab
Also written as “Pembrolizumab”, “Pembrolizumab 200 mg” and “NGM707 plus pembrolizumab (KEYTRUDA®)”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Melanoma · Stomach Neoplasms · Urinary Bladder Neoplasms · Squamous Cell Carcinoma of Head and Neck, led by 8 companies.
Drug pagePembrolizumab: every studyMany companies study it; this page follows only the 148 they lead. All 1,133 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merckits history only | 13823 open or running | phase 4since Oct 19, 2018 | Feb 10, 2011 | Jan 31, 2027phase 3 · NCT04241185 |
| Novartisits history only | 30 open or running | phase 2since May 15, 2019 | Dec 12, 2013 | none ahead |
| PDS Biotechnologyits history only | 20 open or running | phase 3since Jan 14, 2025 | Feb 5, 2020 | none ahead |
| AGO Researchits history only | 11 open or running | phase 2since May 11, 2023 | May 11, 2023 | Oct 30, 2027phase 2 · NCT05903833 |
| EverNov Medicines (Zhuhai Hengqin) | 10 open or running | phase 2since Dec 29, 2020 | Dec 29, 2020 | none ahead |
| Mediclinic Middle Eastits history only | 10 open or running | phase 2since Mar 14, 2019 | Mar 14, 2019 | none ahead |
| NovoCureits history only | 11 open or running | phase 3since Aug 13, 2024 | Aug 13, 2024 | Apr 2029phase 3 · NCT06556563 |
| TiumBioits history only | 11 open or running | phase 2since Feb 20, 2023 | Feb 20, 2023 | Dec 2026phase 2 · NCT05784688 |
Also a collaborator on its studies: Pfizer, Eisai, Astellas Pharma, Novotech (Australia) Pty and Medidata Solutions.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of EverNov Medicines (Zhuhai Hengqin) only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 29, 2020First study: phase 2 study in Advanced Solid TumorsFirst studyNCT04699643 · 80 enrolled · China
TargetBeta
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
The one study EverNov Medicines (Zhuhai Hengqin) leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04699643Advanced Solid Tumors · China | 2 | UNKNOWN | Jun 2023 | 80 |
How it is read
Names in the registry
- “Pembrolizumab”, 124 entries
- “pembrolizumab”, 29 entries
- “Pembrolizumab 200 mg”, 7 entries
- “NGM707 plus pembrolizumab (KEYTRUDA®)”, 4 entries
- “GV20-0251 and Pembrolizumab [KEYTRUDA®]”, 2 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 29 studies
- Melanoma, 14 studies
- Stomach Neoplasms, 10 studies
- Urinary Bladder Neoplasms, 9 studies
- Squamous Cell Carcinoma of Head and Neck, 9 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.